Cotiviti nears $3 billion deal to acquire Edifecs, rejecting higher bid from UnitedHealth. Antitrust concerns cited.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

In a report released today, Jade Rahmani from KBW maintained a Buy rating on Kkr Real Estate Finance (KREF – Research Report), with a price ...

With England and India are playing their first ODI match at the Vidarbha Cricket Association Stadium in Nagpur on February 6, ...

Q4 2024 Earnings Call Transcript February 4, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.32, ...

Evercore ISI analyst Glenn Schorr maintained a Buy rating on KKR & Co (KKR – Research Report) yesterday and set a price target of $165.00.

Indian pacer Harshit Rana, 23, debuted in One Day Internationals (ODIs) in the opening game of the three-match series against ...

CENTRAL TRUST Co increased its position in KKR & Co. Inc. (NYSE:KKR – Free Report) by 27.0% in the 4th quarter, according to ...

In just his third over, debutant Harshit Rana found himself on the receiving end of a ruthless attack by England's aggressive opener, Phil Salt.

The two US banks’ role in the bid would be to refinance the debt of Seven & i’s US unit, one of the people said. The company ...

KKR-backed healthcare data company Cotiviti is close to securing a deal to buy smaller rival Edifecs for just over $3bn, after it opted against accepting a higher bid from UnitedHealth Group out of ...

Chakravarthy made a comeback to the Indian unit in the home series against Bangladesh in October 2024 and is the leading ...